Straits Times Index
3,322.08 -8.69 (-0.26%) S&P 500
5,358.89 +11.90 (+0.22%) Dow
38,852.17 +53.18 (+0.14%) Nasdaq
17,184.13 +51.01 (+0.30%) Bitcoin USD
69,574.86 -127.08 (-0.18%) CMC Crypto 200
1,444.74 -1.93 (-0.13%)
SLS Oct 2024 1.000 put
| Previous close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.9500 |
| Strike | 1.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.2500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 27 |
GlobeNewswireSELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - - Overall Response Rate (ORR) of 33% and 50% Achieved to Date in 60 mg QW and 30 mg BIW Cohorts, Respectively - - 45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Survival (OS) of 5.4 Months vs. 2.5 Months with Standard of Care; 60 mg Once a Week and 30 mg Twice a Week Median OS Have Not Been Reached Yet - - 100% Overall Response Rate in Patients with ASXL1 Mutation in the 30 mg BIW Co
Simply Wall St.Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - - Announced Positive Phase 2 Data of SLS009 Demonstrating 100% Response Rate in r/r AML Patients with ASXL1 Mutation at 30 mg BIW Dose and 62% Anti-Leukemic Activity Across All Dose Levels; Additional Data Expected in the Secon
